UCB faces U.S. patent challenge for epilepsy drug

May 24, 2016 8:53 AM

19 0

UCB faces U.S. patent challenge for epilepsy drug

The U.S. Patent and Trademark Office (PTO) has begun a trial into whether Belgian pharmaceutical company UCB's patent for an epilepsy drug is valid, said a generic drug company that is challenging UCB's claim.

U.S. pharma group Argentum Pharmaceuticals said in a statement that it had been granted petition by the U.S. PTO for a review against all claims of the sole remaining patent of UCB's Vimpat drug.

Also read: Pebble Discontinuing Smartwatches After Its Sale to Fitbit

Read more

To category page

Loading...